Validity and reliability of the arabic version of the Fremantle back awareness questionnaire

Author: 
Shimaa Ahmed Akl, Samir Ahmed El-Sabbahi and Najlaa Fathi Ewais

Objective: To translate, culturally adapt, validate, and investigate the reliability of Arabic version of Fremantle Back Awareness Questionnaire (FreBAQ-A) for patients with non-specific chronic low back pain (CLBP). Method: Thirty experts (three panels) and 270 non-specific CLBP patients (41.72±7.765years) were recruited for psychometric evaluation. Test–retest as well as internal consistency analyses were used to assess reliability. Intraclass correlation coefficient (95% confidence interval) was used to assess test–retest analysis, whereas Cronbach alpha value was calculated to assess the internal consistency. FreBAQ-A validity was evaluated in forms of face, content, internal, and external construct validity. Demographic parameters, clinical characteristics like pain using numerical rating scale (NRS), Oswestry Disability Index (ODI), and Tampa scale of kinesiophobia (TSK) were assessed along with responses to the study questionnaire. Results: Factor analysis revealed that the Arabic version of FreBAQ has two factorial structures and The FreBAQ-A correlated well with intensity of pain (r = -0.426), duration of the LBP (r = 0.526), disability score (r = 0.381), but no significant relation with TSK score (r = 0.257). The Cronbach alpha in this study for FreBAQ-A was 0.737 Cronbach’s Alpha for which is above 0.7, indicating that the scale Can be considered internally consistent within our sample, and below 0.9 suggesting that None of the items are redundant. It has high test-retest, the ICC value of the total questionnaire score Of FreBAQ-A was 0.96, (P< 0.0001) suggesting that test-retest findings are strongly correlated. Conclusion: The Arabic version of FreBAQ has acceptable psychometric properties of reliability and validity in the evaluation of back altered perception in Arabic‑speaking people with non-specific CLBP and can be useful for use in future research and clinical trials.

Paper No: 
4391